How to tell whether a mushroom supplement contains much mushroom

A jar of mushroom powder says “30% polysaccharides” on the front. That reads like a purity figure. It is closer to a word count.

The most common laboratory test behind that number is a color reaction run with sulfuric acid and phenol, read at a wavelength of 490 nanometers. A 2023 paper in the Journal of Natural Products explains the problem with using it as a quality measure: the method “measures the sugar content of all types of mono-, oligo-, and polysaccharides.”

Starch is a polysaccharide. Maltodextrin, a cheap starch derivative, is a polysaccharide. Table sugar breaks down into sugars the assay sees. So a jar of ground rice could, in principle, post a respectable polysaccharide number and never have contained a mushroom.

The central question with a mushroom supplement is whether there is much mushroom in the jar. One laboratory distinction answers it, and almost no package gives you that distinction.

Two kinds of glucan, and one of them is grain

Fungal cell walls are built largely from beta-glucan, a glucose polymer that is the compound most mushroom research is about. Starch and glycogen are alpha-glucans. They are built from the same sugar, linked a different way, and they are what grain is made of.

That difference is measurable, and the reference method for doing it was published in the Journal of AOAC International in 2016. The procedure works in three steps. Total glucan comes first, by controlled acid hydrolysis with sulfuric acid, with the released glucose measured using a glucose oxidase and peroxidase reagent. Alpha-glucan comes second, measured specifically after enzymes break starch and glycogen down to glucose. Beta-glucan is then calculated as the gap between the two.

Beta-glucan is determined by difference. That one sentence is the most useful technical fact in the whole category, because it means a credible beta-glucan figure requires an alpha-glucan figure, and the alpha-glucan figure is the one that tells you how much grain is in the jar.

The method paper also shows why the number depends on the chemistry chosen. Sulfuric acid gave significantly higher values than hydrochloric acid for reishi and for Poria cocos specifically. Trifluoroacetic acid was much less effective. Purely enzymatic hydrolysis gave much lower values across the board. A disclosure belongs with this: the first author worked at an Irish company that sells the assay kit the paper validates. The chemistry is standard and the journal is a methods journal of long standing, but the method’s champion sells the method.

What real mushrooms contain

To judge a label figure you need to know the plausible range, and a 2020 study in a peer-reviewed environmental health journal supplies it. Polish researchers analyzed 68 samples covering 21 edible species, 18 of them wild and three commercially cultivated, using two different accepted methods.

By the enzymatic method, beta-glucan in the wild fruiting bodies ran from 10.50 to 34.97 grams per 100 grams of dry mass. The three cultivated species ranged from 11.36 to 40.34. Alpha-glucan, the starch-and-glycogen fraction, ran from 0.70 to 8.57 grams per 100 grams in the wild species, and the authors note that published values for both wild and cultivated mushrooms are usually under 10.

That last figure is the practical one. Actual mushroom fruiting body is a low-starch material. A product with a large alpha-glucan or starch reading contains a large amount of something that is not mushroom.

The same study also shows that a bare percentage is not interpretable on its own. Measured by a Congo red dye method, which responds only to beta-glucans with a particular triple-helix shape, the same wild species ran from 1.95 to 17.11 grams per 100 grams, and the cultivated ones from 3.12 to 12.39. For one species the two methods differed by more than 90 percent. Neither method is wrong. They measure different things, and a label that says “30 percent beta-glucan” without naming a method has not told you which.

Fruiting body, mycelium, and the substrate underneath

A mushroom is the fruiting body, the part that looks like a mushroom. Mycelium is the thread-like network the fungus grows as before it fruits, and it is the same organism.

The 2023 Journal of Natural Products paper describes the commercial reality bluntly: many marketed mushroom supplements are made from fungal mycelia grown on sterile rice or other grains, or in liquid media containing a carbohydrate source. When mycelium is grown on grain, the mycelium and the grain are not separable at harvest. The grain is milled in with it.

That is why the glucan distinction stops being academic. Grain is starch. Starch is alpha-glucan. Starch also counts toward a “polysaccharide” figure measured by the 490-nanometer method.

A 2025 analytical study in a peer-reviewed molecular sciences journal demonstrated the chemistry in one named species. Comparing wildcrafted chaga canker against North American chaga supplements, including products containing mycelium fermented on grain, the authors reported that beta-glucan quantification and iodine-starch assays confirmed a starch-rich composition in the fermented grain products and its absence in authentic chaga. Genuine chaga carried triterpenoids such as inotodiol and trametenolic acid plus phenolic compounds, and its melanin absorbance at 500 nanometers separated it from the fermented grain material. Nuclear magnetic resonance fingerprints and mass spectrometry showed what the authors called stark compositional deviations between the three categories.

This finding comes with the largest conflict of interest in the subject, and it has to be stated in the same breath as the result. Five of the paper’s six authors list their affiliation as a company that supplies fruiting-body mushroom extracts, a business that competes directly with producers of mycelium grown on grain. The sixth works at a testing company. The analytical chemistry is checkable and the methods are conventional. The framing is not disinterested. Use the measurements; do not use the paper as a neutral account of the market.

What testing can and cannot show

DNA answers a different question

Genetic identification is often offered as the answer to mushroom authenticity, and it answers something real. A 2017 paper in Food Chemistry barcoded a stretch of ribosomal DNA in 33 fungal samples, including powdered mycelium, grocery-store mushrooms and capsules from commercial supplements, and was able to sequence the region in most of them. The authors point out why it is needed: milling, drying and extraction remove the physical features used to identify species.

But barcoding cannot settle fruiting body against mycelium, because both carry the same fungal DNA. They are the same organism at different life stages. A DNA test can confirm the species on the label is the species in the capsule. It cannot tell you whether you bought a mushroom or a bag of colonized rice.

Only the glucan and starch chemistry separates those two. That is the single most important thing to understand about mushroom product testing claims.

Two disclosures on that 2017 paper: its co-authors included scientists from Procter and Gamble and from a supplement manufacturer, alongside university chemists.

What measurement has found in actual products

The strongest product survey in this category is described inside the 2023 forensics paper rather than retrieved in its own right. It reports that of 19 commercial reishi dietary supplements examined by another research group, only five complied with their label, and 13 contained maltodextrin or other starch-like ingredients that did not come from reishi. The investigators used several independent methods, including thin-layer chromatography, gas chromatography with mass spectrometry, carbohydrate gel electrophoresis and size-exclusion chromatography with light-scattering detection.

That number is reported here at one remove, which is worth saying plainly. The underlying paper was not read for this article, so treat five of 19 as a figure published in a peer-reviewed review rather than one verified at source.

The human evidence, species by species

Here the honest summary is uncomfortable. The marketing is far ahead of the trials.

Lion’s mane

The best-known human cognition trial was published in 2009 in a phytotherapy journal. Thirty Japanese adults aged 50 to 80 with mild cognitive impairment were randomized 15 and 15. The active group took four 250-milligram tablets of 96 percent dried fruiting-body powder three times a day, about 3 grams daily, for 16 weeks, then went four weeks without. Scores on a cognitive scale based on a Japanese dementia screening instrument rose significantly at weeks 8, 12 and 16, and fell significantly four weeks after the supplement stopped.

Two facts belong with that result. The first author’s affiliation is the mushroom laboratory of a Japanese mushroom company, so this is a manufacturer-run trial. And an independent academic review panel assessing lion’s mane in 2024 described a very small, double-blind, placebo-controlled trial in mild cognitive impairment showing temporary improvement, and added that “this finding has yet to be replicated.”

That same 2024 review also noted a single reported case of anaphylaxis after a patient ate fresh lion’s mane.

Later placebo-controlled studies exist, all small and mostly short, with mixed results. A 2019 Japanese trial reported a gain on one of three thinking tests. A 2020 Taiwanese pilot trial in mild Alzheimer’s disease reported benefits, though only a daily-living score differed significantly from placebo, and five of its authors drew salaries from the firm that provided the study materials. Four studies in healthy adults aged 18 to 50, with 18 to 41 people each, found little beyond faster performance on a task here and there after a single dose.

Reishi

A Cochrane review updated in 2016 found five randomized trials in cancer patients. The reviewers reported that the methodological quality of the primary studies was generally unsatisfying and that results were inadequately reported in many respects. No trial recorded long-term survival. Pooled tumor response for reishi alongside chemotherapy or radiotherapy versus those treatments alone gave a relative risk of 1.50 with a 95 percent confidence interval of 0.90 to 2.51, an interval that crosses the line of no effect. Immune cell percentages rose modestly: CD3 by 3.91 percent, CD4 by 3.05 percent, CD8 by 2.02 percent. The reviewers’ conclusion was that the evidence did not justify reishi as a first-line cancer treatment and that whether it prolongs survival remains uncertain.

Turkey tail

The most cited human study is a Phase 1 dose-escalation trial published in 2012. Eleven women who had completed radiotherapy for breast cancer were recruited and nine finished, in three groups of three taking 3, 6 or 9 grams a day for six weeks. Nine adverse events were recorded, seven mild, one moderate and one severe. The immune findings were explicitly reported as trends, and CD4 T cells and one natural killer cell subset did not change. A Phase 1 trial asks whether a dose is tolerable. Nine completers cannot answer whether anything works, and the paper does not claim otherwise.

Cordyceps

The human performance evidence most often invoked is a 2005 study in eight male cyclists. It was double-blind and placebo-controlled, and it found no significant differences in muscle tissue oxygen saturation, maximal oxygen uptake, ventilatory threshold or time to exhaustion. The product tested also combined cordyceps with rhodiola, so it cannot isolate either one. Eight people, a combination product, and a null result.

Chaga

No human efficacy trial was located for this article. What exists instead is harm.

Sorting those findings into tiers

It helps to say out loud which bucket each of these sits in, because product copy blurs them.

Established evidence that a marketed mushroom supplement improves a health outcome in people: none of the above reaches it. Not one of these species has a replicated, adequately sized human efficacy trial.

Preliminary research: lion’s mane for thinking and memory, from a handful of small trials with mixed results, the best known a manufacturer-run trial of 30 people with mild cognitive impairment; reishi as an add-on in cancer care, from five trials the Cochrane reviewers judged methodologically unsatisfying; turkey tail’s immune trends in nine people.

Insufficient evidence: cordyceps for exercise performance, where the human study is eight people, a combination product and a null result; chaga for anything, where no human efficacy trial was found.

Documented harm: chaga and oxalate nephropathy, below.

Tradition belongs in a separate column entirely. The 2024 academic review notes lion’s mane has historically been used as traditional medicine in Asia and Europe, and the nephrologists who published the 2020 chaga case open by noting chaga is widely used in folk remedies and alternative medicine. Both statements are history. Neither is clinical evidence. FDA, for its part, has quoted traditional-use marketing language from company websites, including a claim that lion’s mane had been used for over 2,000 years in Chinese medicine, as part of the record in a warning letter.

The documented harm: oxalate in the kidney tubules

Two peer-reviewed case reports, from two Korean hospital groups, describe the same mechanism.

In a 2020 report, a 49-year-old man arrived with end-stage renal disease. A review of his kidney biopsy showed chronic tubulointerstitial nephritis with oxalate crystal deposits, and his history revealed long-term use of chaga mushroom powder for intractable eczema. The authors measured the oxalate content of his remaining product and found 14.2 grams per 100 grams. They estimated his daily oxalate intake at roughly twice a usual dietary intake for four years, and five times usual for one year, and concluded chaga is a potential risk factor for chronic kidney disease given that oxalate content.

In a 2022 report, a 69-year-old man who had taken 10 to 15 grams of chaga powder a day plus 500 milligrams of vitamin C a day for three months developed acute kidney injury that presented as nephrotic syndrome. Biopsy showed focal acute tubular injury with calcium oxalate crystals in the tubules. He required hemodialysis and high-dose steroids, and his kidney function recovered after a month.

Oxalate is the same compound involved in the most common kind of kidney stone. At high intake it can crystallize inside the kidney’s filtering tubules rather than in the urinary tract. Vitamin C is metabolized partly to oxalate, which is why the 2022 case’s concurrent 500 milligrams a day is noted in the report.

This is the clearest signal in the category that a mushroom powder is not automatically a food-level exposure. Risk concentrates in people with existing kidney impairment, people who are dehydrated, and people taking high-dose vitamin C at the same time.

When this needs a clinician, not a web search. New swelling in the legs or around the eyes, foamy urine, a sharp drop in urine output, or unexplained fatigue with nausea in someone using a concentrated mushroom powder are reasons to be seen promptly and to bring the container. Both published cases were identified only by kidney biopsy, which means a routine visit without the exposure history on the table would likely have missed the cause. Anyone with reduced kidney function, a history of kidney stones, or a kidney transplant has a specific decision to make with a nephrologist rather than a label to read.

What regulators have and have not done

FDA has acted on mushroom supplements. A warning letter dated November 3, 2020 quoted a company’s own marketing, including statements that turkey tail is known to have anti-cancer, antiviral, antibacterial and antifungal effects and that cordyceps produces a compound with antitumor activity in various cancers. FDA cited the Federal Food, Drug, and Cosmetic Act provisions that turn a product with disease claims into an unapproved new drug, along with misbranding provisions.

One citation in that letter is worth knowing about. FDA also invoked 21 CFR 101.93(g)(2)(iv)(C), the provision under which citing a published study in labeling can itself be evidence of a disease claim, when the citation refers to a disease use and the context implies treatment or prevention. Linking to research is not automatically safe marketing.

Here is the gap. That letter, and the comparable ones found for this article, concern claims. No FDA enforcement action was located on grain content, on starch in a mushroom product, or on whether a package that says “mushroom” may contain mycelium grown on rice. As far as this research established, the fruiting-body question has been fought out entirely between commercial parties and in the analytical literature, not by a regulator.

Reading a mushroom label without a laboratory

Four things to look for, in order of how much they tell you.

1. An alpha-glucan or starch figure. Its absence is the most informative thing on most packages. A beta-glucan number without an alpha-glucan number cannot be checked, because beta-glucan is calculated as the difference between total glucan and alpha-glucan.
2. A named assay method. “Beta-glucan, enzymatic method” means something. A bare percentage does not, given that two accepted methods differed by more than 90 percent on the same species.
3. “Polysaccharides” as the headline number. This is the weakest figure in the category. The common test counts every sugar present, including added starch.
4. What part of the organism the ingredient line names. “Mushroom,” “fruiting body,” “mycelium” and “mycelial biomass” are different materials. US labeling practice does not require the growing substrate to be quantified.

The takeaway

The useful question is not whether reishi or lion’s mane or chaga has published research behind it. For most of these species the published human research is one or a few small trials, a Phase 1 safety study, or nothing.

The useful question is whether a given jar contains fungal cell wall or ground grain, and only one measurement answers it: the alpha-glucan figure sitting next to the beta-glucan figure. A product that reports both has told you something. A product that reports “polysaccharides” has told you how much sugar of any kind is in the powder, which is a question nobody was asking.

Sources

1. Journal of AOAC International (PubMed). “McCleary BV, Draga A. "Measurement of beta-Glucan in Mushrooms and Mycelial Products." J AOAC Int, 2016. PubMed. DOI: 10.5740/jaoacint.15-0289.” pubmed.ncbi.nlm.nih.gov
2. Journal of Natural Products (PubMed). “Gafner S, et al. "Botanical Ingredient Forensics: Detection of Attempts to Deceive Commonly Used Analytical Methods for Authenticating Herbal Dietary and Food Ingredients and Supplements." J Nat Prod, 2023. PubMed. DOI: 10.1021/acs.jnatprod.2c00929.” pubmed.ncbi.nlm.nih.gov
3. International Journal of Molecular Sciences (PubMed). “Windsor C, et al. "Comparative Study of Chaga (Inonotus obliquus) Dietary Supplements Using Complementary Analytical Techniques." Int J Mol Sci, 2025. PubMed. DOI: 10.3390/ijms26072970.” pubmed.ncbi.nlm.nih.gov
4. International Journal of Environmental Research and Public Health (PubMed). “Mironczuk-Chodakowska I, Witkowska AM. "Evaluation of Polish Wild Mushrooms as Beta-Glucan Sources." Int J Environ Res Public Health, 2020. PubMed. DOI: 10.3390/ijerph17197299.” pubmed.ncbi.nlm.nih.gov
5. Food Chemistry (PubMed). “Raja HA, et al. "DNA barcoding for identification of consumer-relevant mushrooms: A partial solution for product certification?" Food Chem, 2017;214:383-392. PubMed. DOI: 10.1016/j.foodchem.2016.07.052.” pubmed.ncbi.nlm.nih.gov
6. Phytotherapy Research (PubMed). “Mori K, et al. "Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial." Phytother Res, 2009. PubMed. DOI: 10.1002/ptr.2634.” pubmed.ncbi.nlm.nih.gov
7. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (PubMed). “Muhanna M, et al. "ALSUntangled #73: Lion's Mane." Amyotroph Lateral Scler Frontotemporal Degener, 2024. PubMed. DOI: 10.1080/21678421.2023.2296557.” pubmed.ncbi.nlm.nih.gov
8. Biomedical Research (Tokyo) (PubMed). “Saitsu Y, et al. "Improvement of cognitive functions by oral intake of Hericium erinaceus." Biomed Res, 2019. PubMed. DOI: 10.2220/biomedres.40.125.” pubmed.ncbi.nlm.nih.gov
9. Frontiers in Aging Neuroscience (PubMed). “Li IC, et al. "Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study." Front Aging Neurosci, 2020. PubMed. DOI: 10.3389/fnagi.2020.00155.” pubmed.ncbi.nlm.nih.gov
10. International Journal of Exercise Science (PubMed). “Grozier CD, et al. "Four Weeks of Hericium erinaceus Supplementation Does Not Impact Markers of Metabolic Flexibility or Cognition." Int J Exerc Sci, 2022. PubMed. DOI: 10.70252/XZKO8571.” pubmed.ncbi.nlm.nih.gov
11. Nutrients (PubMed). “Docherty S, et al. "The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study." Nutrients, 2023. PubMed. DOI: 10.3390/nu15224842.” pubmed.ncbi.nlm.nih.gov
12. Nutrients (PubMed). “La Monica MB, et al. "Acute Effects of Naturally Occurring Guayusa Tea and Nordic Lion's Mane Extracts on Cognitive Performance." Nutrients, 2023. PubMed. DOI: 10.3390/nu15245018.” pubmed.ncbi.nlm.nih.gov
13. Frontiers in Nutrition (PubMed). “Surendran G, et al. "Acute effects of a standardised extract of Hericium erinaceus (Lion's Mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study." Front Nutr, 2025. PubMed. DOI: 10.3389/fnut.2025.1405796.” pubmed.ncbi.nlm.nih.gov
14. Cochrane Database of Systematic Reviews (PubMed). “Jin X, et al. "Ganoderma lucidum (Reishi mushroom) for cancer treatment." Cochrane Database Syst Rev, 2016. PubMed. DOI: 10.1002/14651858.CD007731.pub3.” pubmed.ncbi.nlm.nih.gov
15. ISRN Oncology (PubMed). “Torkelson CJ, et al. "Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer." ISRN Oncol, 2012. PubMed. DOI: 10.5402/2012/251632.” pubmed.ncbi.nlm.nih.gov
16. Journal of Strength and Conditioning Research (PubMed). “Colson SN, et al. "Cordyceps sinensis- and Rhodiola rosea-based supplementation in male cyclists and its effect on muscle tissue oxygen saturation." J Strength Cond Res, 2005. PubMed. DOI: 10.1519/R-15844.1.” pubmed.ncbi.nlm.nih.gov
17. Journal of Korean Medical Science (PubMed). “Lee S, et al. "Development of End Stage Renal Disease after Long-Term Ingestion of Chaga Mushroom: Case Report and Review of Literature." J Korean Med Sci, 2020. PubMed. DOI: 10.3346/jkms.2020.35.e122.” pubmed.ncbi.nlm.nih.gov
18. Medicine (Baltimore) (PubMed). “Kwon O, et al. "Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: A case report." Medicine (Baltimore), 2022. PubMed. DOI: 10.1097/MD.0000000000028997.” pubmed.ncbi.nlm.nih.gov
19. U.S. Food and Drug Administration. “Warning Letter 609440, November 3, 2020 (mushroom dietary supplements, disease claims).” fda.gov